← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
AntibodySanofiApproved

Dupilumab SAR231893 (Dupilumab SAR231893)

Chronic Obstructive Pulmonary Disease · Dermatitis Atopic

#DermatitisAtopic#Antibody#Approved#인기#항체+5
효능 ORR 0.44%임상시험 57상태 ACTIVE
AntibodyPfizerPhase 3

Elotuzumab (Elotuzumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+4
효능 ORR 100%임상시험 57상태 RECRUITING
CGTBiologicMultan Medical And Dental Colle…Phase 2

Isotretinoin (Isotretinoin)

Neuroblastoma · Neuroblastoma

#Neuroblastoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 95.4%임상시험 57상태 DISCONTINUED
CGTBiologicGilead SciencesPreclinical

Ledipasvir-Sofosbuvir (Ledipasvir-Sofosbuvir)

Chronic Hepatitis C (Disorder) · Chronic Hepatitis C

#ChronicHepatitisC#CGT#Preclinical#인기#세포유전치료+5
효능 ORR 1.5%임상시험 57상태 ACTIVE
CGTBiologicImmunityBio, Inc.vedotin (BT8009) and dual-A…Phase 2

IL-15 Superagonist (N-803, N-803 (IL-15 Superagonist))

High-risk Prostate Cancer · High-risk Prostate Cancer

#High-riskProstateCancer#CGT#Phase2#인기#세포유전치료+5
효능 ORR 80%임상시험 57상태 DISCONTINUED
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab monotherapy)

Advanced Metastatic Cancer; Advanced Prostate Cancer · Genitourinary Cancers

#GenitourinaryCancers#Antibody#Phase2#인기#항체+5
효능 ORR 59%임상시험 57상태 RECRUITING
ADCBiologicPfizerderuxtecan and tucatinibPhase 3

Tucatinib (Tucatinib)

Dynamic Tumor Resistance; Metastatic Colorectal Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 100%임상시험 57상태 RECRUITING
ADCBiologicRocheDM1 via butelase-1 with ABD…Phase 2

ado-trastuzumab emtansine (Kadcyla, T-DM1)

Bone Metastases; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 57상태 ACTIVE
CGTBiologicImmunityBio, Inc.Phase 2

ALT-803 (ALT-803)

Melanoma · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase2#인기#세포유전치료+5
효능 ORR 33%임상시험 56상태 DISCONTINUED
ADCBiologicEpizyme, Inc.Phase 2

Abiraterone + prednisone (Abiraterone + prednisone)

Metastatic Prostate Cancer; Metastatic Castration-resistant Prostate Cancer · mCRPC

#mCRPC#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 46%임상시험 56상태 RECRUITING
AntibodyAbbVieApproved

adalimumab (Humira, Adalimumab treatment arm)

Psoriasis; Cardiovascular Diseases · Psoriasis

#Psoriasis#Antibody#Approved#인기#항체+5
효능 ORR 2%임상시험 56상태 ACTIVE
CGTBiologicMarzieh EbrahimiPhase 1

Allogenic NK cells infusion (Allogenic NK cells infusion)

Neuroblastoma, Recurrent, Refractory; Neuroblastoma (NB) · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 5%임상시험 56상태 RECRUITING
CGTBiologicMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#인기#세포유전치료+5
효능 ORR 97.1%임상시험 56상태 RECRUITING
ADCBiologicSeagenvedotin-containing regimen …Phase 2

BV (BrentuximabVedotin, BrentuximabVedotin (BV))

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 2%임상시험 56상태 ACTIVE
CGTBiologicJiangsu Topcel-KH Pharmaceutica…Phase 2

CD19 CAR T Arm (CD19 CAR T Arm)

Scleroderma, Systemic · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 16.7%임상시험 56상태 RECRUITING
CGTBiologicAllife Medical Science and Tech…Phase 3

Cytokine-induced killer cells (Cytokine-induced killer cells)

Cholangiocarcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#CGT#Phase3#인기#세포유전치료+4
효능 30%임상시험 56상태 RECRUITING
CGTBiologicBristol-Myers SquibbPreclinical

Daclatasvir-Sofosbuvir (Daclatasvir-Sofosbuvir)

Chronic Hepatitis C (Disorder) · Chronic Hepatitis C

#ChronicHepatitisC#CGT#Preclinical#인기#세포유전치료+4
효능 ORR 97%임상시험 56상태 ACTIVE
AntibodyIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+5
효능 ORR 67%임상시험 56상태 RECRUITING
AntibodyAstraZenecavedotin combined with pembr…Phase 3

durvalumab (Imfinzi, MEDI4736, MEDI4736 (Durvalumab) + Tremelimumab)

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 56상태 RECRUITING
ADCBiologicBeijing InnoCare Pharma Tech Co…Phase 3

Orelabrutinib (Orelabrutinib)

Primary Central Nervous System Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#ADC#Phase3#인기#항체약물접합체+3
임상시험 56상태 RECRUITING

19 / 209 페이지

← 이전다음 →